A Comparative Study of Pioglitazone and Ursodeoxycholic Acid in the Treatment of Non-Alcoholic Fatty Liver Disease in a Tertiary Care Center in Northeastern India

2018 ◽  
Vol 5 (2) ◽  
pp. 47
Author(s):  
Kapil Hazarika ◽  
Mangala Lahkar ◽  
Bikash Narayan Choudhury
Keyword(s):  
Liver Disease ◽  
Comparative Study ◽  
Fatty Liver ◽  
Ursodeoxycholic Acid ◽  
Fatty Liver Disease ◽  
Care Center ◽  
Tertiary Care ◽  
Tertiary Care Center ◽  
Alcoholic Fatty Liver ◽  
Alcoholic Fatty Liver Disease

scholarly journals Burden of Alcoholic Liver Disease in a Tertiary Care Center: A Descriptive Cross-sectional Study

2019 ◽  
Vol 57 (219) ◽  
Author(s):  
Shikha Rizal ◽  
Bishal Raj Joshi ◽  
Arambam Giridhari Singh
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Alcoholic Liver Disease ◽  
Fatty Liver Disease ◽  
Care Center ◽  
Tertiary Care ◽  
Tertiary Care Center ◽  
Cross Sectional ◽  
Alcoholic Fatty Liver ◽  
Alcoholic Fatty Liver Disease

Introduction: Alcoholic liver disease is a serious health problem related to an unhealthy lifestyle. The three most widely recognized forms of alcoholic liver disease are alcoholic fatty liver, acute alcoholic hepatitis, and alcoholic cirrhosis. The main aim of our study is to find out the prevalence of alcoholic liver disease in tertiary care center. Methods: A descriptive cross-sectional study was conducted among inpatient cases admitted in the medicine department of tertiary care center from 1st June 2018 to 31st May 2019. Ethical approval was taken for the study. Convenience sampling method was used. All the biochemical parameters were expressed as mean±standard deviation for each group and point estimate at 95% Confidence Interval was calculated along with frequency and proportion for binary data. Results: Prevalence of alcoholic liver disease is 50 (50%) at a 95% Confidence Interval (40.2%-59.8%) and non-alcoholic fatty liver disease is also the same. The mean age of alcoholic liver disease was 59±12 years where as the mean age for non-alcoholic fatty liver disease was 46±18 years. Out of fifty patients of alcoholic liver disease, majority 48 (96%) of the cases were males which suggests that the prevalence of alcoholic liver disease is very common in males. Similarly, for non-alcoholic fatty liver disease, prevalence was 34 (68%) showing higher prevalence than that of females. Conclusions: Prevalence of alcoholic liver disease is low compared to previous studies done in the similar settings. Monitoring these biochemical parameters in alcoholic liver disease at early stage could guide in planning the protocol for the initial treatment.

scholarly journals Nonalcoholic Fatty Liver Disease and Metabolic Syndrome among patients attending in a tertiary care center in Bangladesh

2018 ◽  
Vol 28 (2) ◽  
pp. 44-51
Author(s):  
MMR Khan ◽  
MK Rahman ◽  
NK Sana ◽  
PM Basak ◽  
BC Sarker ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Liver Disease ◽  
Fatty Liver ◽  
Chronic Liver Disease ◽  
Fatty Liver Disease ◽  
Care Center ◽  
Tertiary Care ◽  
Tertiary Care Center ◽  
Alcoholic Fatty Liver ◽  
Alcoholic Fatty Liver Disease

Non-alcoholic fatty liver disease (NAFLD) is an emerging chronic liver disease and may lead to liver cirrhosis and hepatocellular carcinoma. It is now the most common chronic liver disease in many developed as well as developing countries. This hospital based study was done to see the prevalence of non-alcoholic fatty liver disease (NAFLD) and metabolic syndrome among patients attending in a tertiary care center in Bangladesh. Here, 334 nonalcoholic subjects of both sex and age were included. Metabolic syndrome was assessed by modified ATP III criteria and fatty liver diagnosis was based on ultrasound findings. 27.2% had the metabolic syndrome and was more common in female. Prevalence of NAFLD was 44% and was more common in female. Metabolic syndrome was found in 61.5% with NAFLD.TAJ 2015; 28(2): 44-51

scholarly journals Carotid Intima-media Thickness in Patients with Non-alcoholic Fatty Liver Disease Attending a Tertiary Care Center: A Descriptive Cross-sectional Study

2021 ◽  
Vol 59 (237) ◽  
Author(s):  
Bom BC ◽  
Raj Kishwor Jaiswal ◽  
Prashant Kumar Gupta ◽  
Rajan Paudel ◽  
Raj Kumar Subedi
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Care Center ◽  
Tertiary Care ◽  
Intima Media Thickness ◽  
Carotid Intima Media Thickness ◽  
Alcoholic Fatty Liver ◽  
Media Thickness ◽  
Alcoholic Fatty Liver Disease

Introduction: Non-alcoholic fatty liver disease is fatty infiltration of the liver in the absence of other causes of steatosis. It is strongly associated with central adiposity, high body mass index, insulin resistance states, hypertension, hyperlipidemia which are features of metabolic syndrome. The objective of study is to find out the carotid intima-media thickness of non alcoholic fatty liver disease patients attending a tertiary care center. Methods: This was a descriptive cross sectional study conducted at National Academy of Medical Sciences, Bir Hospital from July 2018 to June 2019 among 70 diagnosed cases of non alcoholic fatty liver disease based on ultrasound findings. Data collection was started after receiving ethical approval from Institutional Review Board of the Institute. Convenience sampling method was used. Data were entered using Microsoft Excel. The carotid intima-media thickness of both sides were measured by ultrasound. Statistical Package for Social Sciences version 20 was used for analysis. Results: Out of 70 cases, the mean carotid intima-media thickness was 0.7140±0.1796mm on right and 0.7161±0.1828mm on left side. Among 70 cases 45 (64.3%) were Grade II non alcoholic fatty liver disease and 25 (35.7%) were Grade I. It was 0.5720±0.1275mm and 0.7929±0.1546mm in Grade I and II non alcoholic fatty liver disease cases respectively on right side whereas it was 0.5676±0.1259mm and 0.7987±0.1557mm respectively on left side. Conclusions: This study showed increased carotid intima-media thickness in non alcoholic fatty liver disease cases.

scholarly journals Prevalence of Non-alcoholic Fatty Liver Disease and Its Associated Factors in Admixed Individuals With Type 1 Diabetes: a Cross-sectional Study in a Tertiary Care Center in Brazil

2021 ◽  
Author(s):  
Bianca Senger Vasconcelos Barros ◽  
Fernanda Cruz Monteiro ◽  
Carlos Terra ◽  
Marilia Brito Gomes
Keyword(s):  
Metabolic Syndrome ◽  
Type 1 Diabetes ◽  
Liver Disease ◽  
Fatty Liver Disease ◽  
Care Center ◽  
Tertiary Care ◽  
Tertiary Care Center ◽  
Alcoholic Fatty Liver ◽  
Alcoholic Fatty Liver Disease

Abstract Background: Data on non-alcoholic fatty liver disease (NAFLD) in admixed individuals with type 1 diabetes (T1D) is lacking. We investigated NAFLD in an admixed population with T1D from a tertiary care center in Brazil. Methods: Ninety-five participants with T1D, aged 39 ± 13 years, with disease duration of 21 ± 9 years, being 55 (57.9%) females, from a university hospital in Rio de Janeiro, were screened for NAFLD with hepatic ultrasound (US) and transient elastography (TE). Results: Prevalence of NAFLD was, respectively, 12.6% and 16.8% when US and TE were used. Fibrosis was present in 8% of participants. A total of 31.6% of participants had at least one of the hepatic exams altered, which was associated with higher anthropometric measurements, presence of metabolic syndrome and higher triglycerides levels, even within the normal range.Conclusion: In our study, prevalence of NAFLD in US approximates from the one found with TE. Screening should be reserved for participants with T1D and metabolic syndrome, as this was the main factor associated with NAFLD. Triglycerides levels were the only component of metabolic syndrome associated with NAFLD. Further studies are necessary to determine the best screening strategy for NAFLD in individuals with T1D from admixed populations.

scholarly journals A 12-week multi-component dietary intervention improves markers of non-alcoholic fatty liver disease in Irish patients in tertiary care

2020 ◽  
Vol 79 (OCE2) ◽  
Author(s):  
Deirdre Ní Fhloinn ◽  
Ciara Wright ◽  
Sara Naimimohasses ◽  
Stephen Finn ◽  
Suzanne Norris ◽  
...  
Keyword(s):  
Weight Loss ◽  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Dietary Intervention ◽  
Tertiary Care ◽  
Intervention Group ◽  
Post Intervention ◽  
Alcoholic Fatty Liver ◽  
Alcoholic Fatty Liver Disease

AbstractNon-alcoholic fatty liver disease (NAFLD) is a significant public health concern closely linked to obesity, affecting an estimated 25% of adults in Europe. Understudied in Ireland, the aim of this research was to examine the effects of a 12-week multi-component dietary intervention on weight loss and markers of liver injury in Irish NAFLD patients in tertiary care. Biopsy confirmed NAFLD patients (n = 27) were recruited from St James’ Hospital in Dublin, Ireland. Consenting participants underwent a 12-week moderate-intensity intervention incorporating weekly group nutritional education, behavioural change and group support, as well as individualised advice and weigh-ins from a trained nutritionist. Control group participants were given routine clinical care. All participants were clinically reviewed before, immediately after, and 3 months post intervention. Individuals (n = 12) with histological evidence of steatohepatitis underwent a repeat liver biopsy on completion of the intervention. Detailed dietary assessment was performed using both a 4-day diet diary (4DDD) and a novel, recently validated, short food frequency questionnaire (SFFQ) designed specifically to assess habitual intakes of food items related to NAFLD. Nutrient intakes were analysed using myFood24TM dietary analysis software, and the Mediterranean diet quality score (MDQS) was used to assess the overall change in dietary patterns. Of the 15 participants who completed the intervention, 80% (n = 12) achieved a weight loss exceeding 5%, with 47% (n = 7) achieving > 7%. There were significant improvements from baseline to week 12 in the intervention group for the majority of clinical parameters including HbA1c (p = 0.0054), liver enzymes (ALT, p = 0.0108; GGT, p = 0.0001) and transient elastography (kPA, p = 0.0308; CAP, p = 0.0081). However, these results failed to maintain significance when analysed compared to controls. The overall dietary pattern was significantly improved after 12 weeks as assessed by the MDQS (p = 0.03), with no apparent compromise in micronutrient intake despite the energy reduction. Reductions in energy, saturated fat, carbohydrate and sugar intakes at 12 weeks, were maintained at three months follow up. Analysis of pre- and post-intervention liver biopsies in the intervention group demonstrated a clinically significant improvement in NAS score (p = 0.0273), attributable to reductions in hepatic steatosis (p = 0.0078). A significant correlation was observed between improvement in liver histology and change in sugar intake (r = 0.7534, p = 0.0093). Although results were somewhat limited by small sample size, nutritional education achieved beneficial dietary changes that persisted after the intervention ceased. Notably, achieving reductions in sugar intakes may be particularly beneficial in reducing the severity of hepatic steatosis in Irish adults with NAFLD.

miR-34a/SIRT1/p53 is suppressed by ursodeoxycholic acid in the rat liver and activated by disease severity in human non-alcoholic fatty liver disease

2013 ◽  
Vol 58 (1) ◽  
pp. 119-125 ◽  
Author(s):  
Rui E. Castro ◽  
Duarte M.S. Ferreira ◽  
Marta B. Afonso ◽  
Pedro M. Borralho ◽  
Mariana V. Machado ◽  
...  
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Ursodeoxycholic Acid ◽  
Disease Severity ◽  
Rat Liver ◽  
Fatty Liver Disease ◽  
Alcoholic Fatty Liver ◽  
Alcoholic Fatty Liver Disease

scholarly journals PREVALENCE OF NON-ALCOHOLIC FATTY LIVER DISEASE IN HYPOTHYROIDISM IN A TERTIARY CARE HOSPITAL IN EASTERN INDIA

2017 ◽  
Vol 6 (79) ◽  
pp. 5589-5593 ◽  
Author(s):  
Rina Mohanty ◽  
Samarendra Nath Das ◽  
Aujjwalya Kumar Jena ◽  
Sarita Behera ◽  
Nirmal Chandra Sahu ◽  
...  
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Tertiary Care Hospital ◽  
Tertiary Care ◽  
Care Hospital ◽  
Eastern India ◽  
Alcoholic Fatty Liver ◽  
Alcoholic Fatty Liver Disease

scholarly journals Effect of Combination Therapy with Atorvastatin and Ursodeoxycholic Acid on the Course of Ischemic Heart Disease with Co-Existent Non-Alcoholic Fatty Liver Disease and Obesity

2016 ◽  
Vol 23 (4) ◽  
pp. 2016420
Author(s):  
Nataliya Karpyshyn
Keyword(s):  
Heart Disease ◽  
Liver Disease ◽  
Ischemic Heart Disease ◽  
Fatty Liver ◽  
Ursodeoxycholic Acid ◽  
Functional Status ◽  
Fatty Liver Disease ◽  
Ischemic Heart ◽  
Alcoholic Fatty Liver ◽  
Alcoholic Fatty Liver Disease

Non-alcoholic fatty liver disease is considered as an independent predictor of cardiovascular diseases which plays an important role in the development of ischemic heart disease. The drug most frequently used for treating this comorbidity is atorvastatin which favours better survival outcomes and is essential in the primary and secondary prevention of cardiovascular diseases. Ursodeoxycholic acid is prescribed as an alternative therapy for ischemic heart disease with co-existent non-alcoholic fatty liver disease and obesity to eliminate statin side effects. The use of ursodeoxycholic acid as a hepatoprotector in comprehensive basic treatment contributes to the improvement of the cardiovascular system in patients with ischemic heart disease as well as the increase in treatment efficacy; it improves the functional status of the liver affecting the major pathogenic mechanisms of the disease.The objective of the research was to study the effect of combined hypolipidemic therapy with atorvastatin and ursodeoxycholic acid on the indices of blood lipids, liver transaminase levels, functional status of the liver and the course of non-alcoholic fatty liver disease in patients with ischemic heart disease and obesity.Materials and methods. 20 patients with ischemic heart disease, co-existent non-alcoholic fatty liver disease and obesity were examined. They received ursodeoxycholic acid in addition to atorvastatin for four weeks. All the patients underwent clinical tests, visceral ultrasonography, blood lipid test, liver transaminase test and 13C-methacetin breath test.Results. The study revealed a significant decrease in the level of the pro-atherogenic fractions of blood lipids (р<0.01) as well as an improved functional status of the liver due to a significant increase in metabolic capacity of the liver and cumulative dose on the 40th and 120th minutes after ursodeoxycholic acid administration (р<0.01).Conclusions. The use of ursodeoxycholic acid in addition to atorvastatin in patients with ischemic heart disease, co-existent non-alcoholic fatty liver disease and obesity makes it possible to avoid the adverse effect of hypolipidemic therapy on the functional status of the liver.

Sign in / Sign up

Export Citation Format

Share Document